Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 48%
Buy 38%
Hold 10%
Sell 5%
Strong Sell 0%

Bulls say

DexCom is poised for financial growth driven by key momentum factors, including Medicare expansion and the anticipated positive outcomes from RCT data expected in 2026, which may lead to additional coverage wins that increase the number of covered lives. The company has also made significant strides with its product line, notably the G7 continuous glucose monitoring system, which offers improved sensor longevity and is anticipated to increase adoption rates, further supporting revenue growth. With operational efficiencies and margin improvements projected, DexCom is well-positioned to achieve mid-teens revenue growth along with over 20% EPS growth through 2028.

Bears say

DexCom's sensor revenue of $1.18 billion for the year showed a positive growth rate of 20% year-over-year; however, its hardware revenue experienced a significant decline of 31%, indicating challenges in product sales diversification. The company's forward guidance for fiscal year 2026 revenue of $5.16 billion to $5.25 billion represents a slower growth rate than anticipated, suggesting potential bearish sentiment among investors due to decelerating sales trends and shifts toward lower-margin pharmacy business. Furthermore, the expected sequential revenue decline of 6%-7% in Q1 2026 raises concerns regarding the sustainability of revenue growth and could lead to further downward pressure on DexCom's stock price as sales estimates are likely to be revised lower.

DexCom (DXCM) has been analyzed by 21 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 38% recommend Buy, 10% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 21 analysts, DexCom (DXCM) has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.